Report sees strong year ahead for life sciences IPOs despite headwinds
The report, by law firm WSGR, noted an almost twofold increase in life sciences IPOs - especially biotech - and a greater number priced at $250 million or more.
Wilson Sonsini tops Life Sciences Law Firm Index for 2nd straight year
The Life Sciences Law Firm Index identifies the most active and relevant firms for life science companies.
Understanding EGPA: The Role of Eosinophils and Advancements in Treatment Options
FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.
Is it warranted to be pessimistic about the current state of digital health?
As Lisa Suennen said about this year's JP Morgan Healthcare Conference, "There was a lot of optimism about the convergence of biotech, life sciences and health IT, but also there was a sense of foreboding that the party is over in some of these areas."
This week on MedHeads: A look back at the 2016 JP Morgan Healthcare Conference
This week we will be looking back at 2016 JP Morgan Healthcare Conference: what was said, the big news and what it means for the business of healthcare going forward.